Notably, FOXC1 is consistently present in basal-like breast cancer, an intrinsic subtype that comprises the majority of triple-negative tumors [7], and its detrimental role is indicated by its activation of NF-κB signaling [8], induction of epithelial-to-mesenchymal transition [9], promotion of breast cancer stem cell properties [10], and downregulation of ER expression [11]. This evidence concerns the gene ESR1 and breast carcinoma.